Bavarian Nordic awarded a USD 100 million contract from US Government to further develop drug as safe smallpox vaccine

01-Oct-2004

The National Institute of Allergy and infectious diseases (NIAID), part of the US National Institutes of Health, today awarded Bavarian Nordic A/S a three-year contract to further develop its patented IMVAMUNE(TM) as a safe smallpox vaccine. The value of the contract is more than USD 100 million and is effective immediately.

The contract calls for the manufacture of 500,000 doses of IMVAMUNE(TM) vaccine within 11 months of con-tract award using the final validated production process. It also outlines an option for the US government to purchase an additional 2,5 million doses of IMVAMUNE(TM) vaccine during the contract period for a further USD 41 million. In addition, the contract requires further clinical development of IMVAMUNE(TM) and validation of animal models.

This is the second smallpox vaccine development contract awarded to Bavarian Nordic from NIAID. The first contract was awarded to the company in February 2003 followed by a supplemental award in September 2003.

As mentioned previously, GlaxoSmithKline will collaborate with Bavarian Nordic as a commercial partner in future US government programmes, including the forthcoming Request for Proposal-lll (RFP-lll) which is expected to include the purchase of up to 60 million doses of MVA smallpox vaccine. RFP-lll is expected to be issued before year-end.

The announcement of the US Government award is not expected to affect Bavarian Nordic's expectations for 2004, which remain a turnover of DKK 400 million and a net income before tax of DKK 60-80 million.

https://www.bionity.com/en/news/39907/bavarian-nordic-awarded-a-usd-100-million-contract-from-us-government-to-further-develop-drug-as-safe-smallpox-vaccine.html